The inability of reliably predicting disease severity may result in severely affected SMA patients (e.g. with 4 SMN2 copies) being denied pre-emptive treatment and at the same time mildly affected patients being subject to costly and invasive therapies, many years before first symptoms arise. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.